• Je něco špatně v tomto záznamu ?

The Ups and Downs of BACE1: Walking a Fine Line between Neurocognitive and Other Psychiatric Symptoms of Alzheimer's Disease

SV. Ovsepian, J. Horacek, VB. O'Leary, C. Hoschl

. 2021 ; 27 (3) : 222-234. [pub] 20200725

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc22012430

Although neurocognitive deficit is the best-recognized indicator of Alzheimer's disease (AD), psychotic and other noncognitive symptoms are the prime cause of institutionalization. BACE1 is the rate-limiting enzyme in the production of Aβ of AD, and one of the promising therapeutic targets in countering cognitive decline and amyloid pathology. Changes in BACE1 activity have also emerged to cause significant noncognitive neuropsychiatric symptoms and impairments of circadian rhythms, as evident from clinical trials and reports in transgenic models. In this study, we consider key characteristics of BACE1 with its contribution to neurocognitive deficit and other psychiatric symptoms of AD. We argue that a growing list of noncognitive mental impairments related to pharmacological modulation of BACE1 might present a major obstacle in clinical translation of emerging therapeutic leads targeting this protease. The adverse effects of BACE1 inhibition on mental health call for a revision of treatment strategies that assume indiscriminate inhibition of this key protease, and stress the need for further mechanistic and translational studies.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22012430
003      
CZ-PrNML
005      
20220506130131.0
007      
ta
008      
220425s2021 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1177/1073858420940943 $2 doi
035    __
$a (PubMed)32713260
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Ovsepian, Saak V $u National Institute of Mental Health, Klecany, Czech Republic $u Department of Psychiatry and Medical Psychology, Third Faculty of Medicine, Charles University, Prague, Czech Republic $u International Centre for Neurotherapeutics, Dublin City University, Dublin, Ireland $1 https://orcid.org/0000000295224159
245    14
$a The Ups and Downs of BACE1: Walking a Fine Line between Neurocognitive and Other Psychiatric Symptoms of Alzheimer's Disease / $c SV. Ovsepian, J. Horacek, VB. O'Leary, C. Hoschl
520    9_
$a Although neurocognitive deficit is the best-recognized indicator of Alzheimer's disease (AD), psychotic and other noncognitive symptoms are the prime cause of institutionalization. BACE1 is the rate-limiting enzyme in the production of Aβ of AD, and one of the promising therapeutic targets in countering cognitive decline and amyloid pathology. Changes in BACE1 activity have also emerged to cause significant noncognitive neuropsychiatric symptoms and impairments of circadian rhythms, as evident from clinical trials and reports in transgenic models. In this study, we consider key characteristics of BACE1 with its contribution to neurocognitive deficit and other psychiatric symptoms of AD. We argue that a growing list of noncognitive mental impairments related to pharmacological modulation of BACE1 might present a major obstacle in clinical translation of emerging therapeutic leads targeting this protease. The adverse effects of BACE1 inhibition on mental health call for a revision of treatment strategies that assume indiscriminate inhibition of this key protease, and stress the need for further mechanistic and translational studies.
650    12
$a Alzheimerova nemoc $7 D000544
650    12
$a sekretasy $7 D053829
650    _2
$a amyloidní beta-protein $7 D016229
650    _2
$a aspartátové endopeptidasy $7 D016282
650    _2
$a lidé $7 D006801
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Horacek, Jiri $u National Institute of Mental Health, Klecany, Czech Republic
700    1_
$a O'Leary, Valerie B $u Department of Medical Genetics, Third Faculty of Medicine, Charles University, Prague, Czech Republic
700    1_
$a Hoschl, Cyril $u National Institute of Mental Health, Klecany, Czech Republic $u Department of Psychiatry and Medical Psychology, Third Faculty of Medicine, Charles University, Prague, Czech Republic
773    0_
$w MED00003510 $t The Neuroscientist : a review journal bringing neurobiology, neurology and psychiatry $x 1089-4098 $g Roč. 27, č. 3 (2021), s. 222-234
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32713260 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220425 $b ABA008
991    __
$a 20220506130123 $b ABA008
999    __
$a ok $b bmc $g 1789855 $s 1163631
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 27 $c 3 $d 222-234 $e 20200725 $i 1089-4098 $m The Neuroscientist $n Neuroscientist $x MED00003510
LZP    __
$a Pubmed-20220425

Najít záznam

Citační ukazatele

Možnosti archivace